ScreenerHero

INABIN8bio Inc. Common Stock

NAS · US · Healthcare · Biotechnology · in8bio.com
1.280USD+6.67%Mkt Cap: 12.62M $P/E: —

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lea…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap12.62M $
Enterprise Value-3.85M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-19.44M $
Revenue/Share—
Last Price1.280 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees18
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.25
PEG—
EV/EBITDA0.22
EV/Revenue—
P/S—
P/B0.65
EPS (TTM)-1.30
EPS (Forward)-0.96
52W Range
0.880022% of range2.730
52W High2.730 USD
52W Low0.8800 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-70.54%
ROA-60.22%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-12.71M $
CapEx (TTM)—
FCF Margin—
FCF Yield-62.73%
Net Debt-15.78M $
Net Debt/EBITDA0.89
Balance Sheet
Debt/Equity0.10
Current Ratio8.21
Quick Ratio7.97
Book Value/Sh1.864 USD
Cash/Share1.821 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:30
Split DateJun 6, 2025
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)6.250 USD
Upside (mean)+388.3%
Target Range4.000 USD – 10.00 USD
$4.000+388.3% to mean$10.00
# Analysts4
Ownership
Shares Out.9.86M
Float7.19M
Insiders13.38%
Institutions38.45%
Short Interest
Short Ratio0.5d
Short % Float0.28%
Short % Out.0.25%
Shares Short24.91K
Short (prev mo.)35.12K
Technical
SMA 501.260 (+1.6%)
SMA 2001.631 (-21.5%)
Beta0.28
S&P 52W Chg18.16%
Avg Vol (30d)72.07K
Avg Vol (10d)86.22K
Technical Indicators
RSI (14)59.2
MACD-0.0318
MACD Signal-0.0714
MACD Hist.+0.0396
BB Upper1.279 USD
BB Middle1.081 USD
BB Lower0.8839 USD
BB Width36.52%
ATR (14)0.0991 USD
Vol Ratio (20d)1.13x